Biopharmaceuticals
Cardiology
FDA
News Release - February 2, 2007
GlaxoSmithKline Receives Approvable Letter for New Indications for ARIXTRA(R) (Fondaparinux Sodium) Injection
PHILADELPHIA, Feb. 2 (HSMN NewsFeed) -- GlaxoSmithKline (GSK) announced today that the U.S. Food and Drug Administration (FDA) has issued an approvable letter for the once-daily anticoagulant, ARIXTRA (fondaparinux sodium) Injection, for the treatment of patients with
- Unstable angina or non-ST segment elevation myocardial infarction (UA/NSTEMI)
- ST-segment elevation myocardial infarction (STEMI).
- UA/NSTEMI and STEMI are types of acute coronary syndromes (ACS).
The FDA priority review was completed in six months. GSK will continue to work with the FDA to provide the additional information requested to complete the assessment of ARIXTRA for these indications. The company looks forward to making ARIXTRA available as an additional treatment option for the care of a broad range of patients with acute coronary syndromes. Results of the clinical studies (OASIS 5 and OASIS 6) supporting these two New Drug Applications have been presented and published in New England Journal of Medicine and Journal of the American Medical Association, respectively.
GlaxoSmithKline is one of the world's leading research-based pharmaceutical and healthcare companies. GlaxoSmithKline is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For company information visit http://www.GSK.com.
Source: GlaxoSmithKline
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
